| Date | Title | Description |
| 25.09.2024 | Nxera Pharma receives approval of QUVIVIQ (daridorexant) in Japan for the treatment of insomnia | The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpoints
Plans to make QUVIVIQ available as... |
| 20.03.2024 | Sosei Group Co., Ltd. Announcement of administration of EP4 receptor agonist HTL0033744, a candidate drug for the treatment of inflammatory bowel disease (IBD), to the first subject in a Phase I clini... | Sosei Group Co., Ltd.
Announcement of administration of first subject in Phase I clinical trial of EP4 receptor agonist HTL0033744, a potential treatment for inflammatory bowel disease (IBD)
HTL0033744 is designed to promote mucosal healing... |
| 20.03.2024 | Sosei Group Co., Ltd. Completion of reacquisition of rights to HTL0027477, a first-class treatment candidate for inflammatory bowel disease, GPR35 receptor agonist | - |
| 20.03.2024 | Sosei Group Co., Ltd. Announcement of administration of EP4 receptor agonist HTL0033744, a candidate drug for the treatment of inflammatory bowel disease (IBD), to the first subject in a Phase I clini... | - |
| 20.03.2024 | Sosei Group Co., Ltd. Completion of reacquisition of rights to HTL0027477, a first-class treatment candidate for inflammatory bowel disease, GPR35 receptor agonist | Sosei Group Co., Ltd.
Completion of reacquisition of rights to HTL0027477, a first-class treatment candidate for inflammatory bowel disease, GPR35 receptor agonist
……
The Group has announced that HTL0027477 (GSK4381406), a selective oral GP... |
| 11.03.2024 | Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia | - |
| 06.03.2024 | Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals | - |
| 07.12.2023 | Sosei Group Co., Ltd. Approval for manufacturing and sales of Pivratz(R) Intravenous Injection 150mg (clazosentan sodium) in South Korea | - |
| 07.12.2023 | Sosei Group Co., Ltd. Approval for manufacturing and sales of Pivratz(R) Intravenous Injection 150mg (clazosentan sodium) in South Korea | Sosei Group Co., Ltd.
Approval for manufacturing and sales of Pivratz(R) Intravenous Injection 150mg (clazosentan sodium) in South Korea
……
Obtained manufacturing and sales approval in South Korea for Pivratz (R), a drug that suppresses cer... |
| 11.11.2022 | Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2022 | /EIN News/ -- TOKYO and CAMBRIDGE, United Kingdom, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter ... |
| 10.02.2022 | Sosei : Consolidated Financial Results for the FY2021 (IFRS) | Consolidated Financial Results for the FY2021 (IFRS)
February 10, 2022
Company name: Sosei Group Corporation Listing: Tokyo Stock Exchange
Security code: 4565 URL: https://www.soseiheptares.com/ Representative: Shinichi Tamura Representativ... |
| 06.01.2022 | Verily, Sosei Heptares Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases | What You Should Know:
– Verily and Sosei Heptares announced a new research collaboration combining Verily’s Immune Profiler platform, a next gen immune mapping platform, with Sosei Heptares’ world-leading StaR (stabilized receptor) platform... |
| 06.01.2022 | Sosei and Verily partner on GPCRs; ObsEva touts PhIII data in endometriosis pain | Sosei Heptares is teaming up with a big-name partner: Alphabet’s Verily.
No financials were disclosed, but the pair will aim to use Verily’s immune profiling and Sosei Heptares’ GPCR drug design capabilities to devel... |
| 24.12.2021 | Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences | TOKYO, Japan and CAMBRIDGE, United Kingdom, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) today announces that in connection with the Collaboration and License Agreement (“License Agreement”) with N... |
| 07.12.2021 | Sosei : Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19 | Funding comes through the Covid-19 Therapeutics Accelerator, which was set up by Wellcome, Bill & Melinda Gates Foundation and Mastercard
Tokyo, Japan and Cambridge, UK, 7 December 2021 - Sosei Group Corporation ("the Company"... |
| 26.11.2021 | Sosei : Investor Webinar Q&A - Collaboration with Neurocrine Biosciences to Develop Novel Muscarinic Receptor Agonists | NON - CONFIDENTIAL
Collaboration with Neurocrine Biosciences to Develop Novel Muscarinic Receptor Agonists
For Schizophrenia and Other Neuropsychiatric Disorders
2021 | © Sosei Group Corporation
Disclaimer
The material that follows is a pre... |
| 22.11.2021 | Neurocrine Biosciences : and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders - Form 8-K | Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
Neurocrine Biosciences anticipates initiating a Phase 2 study with the sel... |
| 22.11.2021 | Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders | SAN DIEGO and TOKYO and CAMBRIDGE, England, Nov. 22, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Sosei Group Corporation ("Sosei Heptares"; TSE: 4565) announce the signing of a strategic collaboration and ... |
| 17.11.2021 | Sosei : Jefferies London Healthcare Conference 2021 Presentation | NON - CONFIDENTIAL
World leading drug discovery targeting GPCRs
Corporate Presentation
2021 | © Sosei Group Corporation
Disclaimer
The material that follows is a presentation of general background information about Sosei Group Corporation a... |
| 16.11.2021 | Sosei : Heptares to present at the Jefferies London Healthcare Conference 2021 | Tokyo, Japan and Cambridge, UK, 16 November 2021 - Sosei Group Corporation ("the Company"; TSE: 4565) announces its Chief Financial Officer, Chris Cargill, will present at the Jefferies London Healthcare Conference 2021 today, Tue... |
| 11.11.2021 | Sosei Heptares Operational Highlights and Consolidated Results for Nine Months ended 30 September 2021 | PRESS RELEASE
Sosei Heptares Operational Highlights and Consolidated Results for Nine Months ended 30 September 2021
Tokyo, Japan and Cambridge, UK, 11 November 2021 - Sosei Group Corporation ("the Company"; TSE: 4565) provides an... |
| 11.11.2021 | Quarterly Report for the Third Quarter of 2021 (Quarter ended September 30, 2021) | Sosei Group Corporation
Quarterly Report for the Third Quarter of 2021
(Quarter ended September 30, 2021)
This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this... |
| 11.11.2021 | Consolidated Financial Results for the Nine Month Period Ended September 30, 2021 (IFRS) | Consolidated Financial Results for the Nine Month Period Ended September 30, 2021 (IFRS)
November 11, 2021
Company name: Sosei Group Corporation Listing: Tokyo Stock Exchange
Security code: 4565 URL: https://www.soseiheptares.com/ Represent... |
| 12.08.2021 | Sosei : Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half 2021 | Tokyo, Japan and Cambridge, UK, 12 August 2021 - Sosei Group Corporation ('the Company'; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2021.
... |
| 12.08.2021 | Sosei : H1 FY2021 Financial Results Presentation | NON-CONFIDENTIAL
H1 FY2021 Financial Results
Six-month period ended June 30, 2021
August 12, 2021 | Sosei Group Corporation (TSE:4565)
Disclaimer
The material that follows is a presentation of general background information about Sosei Grou... |
| 08.07.2021 | Sosei : Announces Determination of the Issuance Terms for its Convertible Bonds | PRESS RELEASE
Sosei Announces Determination of the Issuance Terms for its Convertible Bonds
Tokyo, Japan and Cambridge, UK, 7 July 2021 - Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announces that it has determined ... |
| 07.07.2021 | Sosei : Announces Issuance of Convertible Bonds and Buyback of Existing Convertible Bonds | PRESS RELEASE
Sosei Announces Issuance of Convertible Bonds and Buyback of Existing Convertible Bonds
Tokyo, Japan, and Cambridge, UK, 7 July 2021 - Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) today announces that i... |
| 23.06.2021 | Sosei : Heptares Initiates Phase 1 Trial with Novel Small-Molecule CGRP Antagonist under Collaboration with Biohaven | PRESS RELEASE
Sosei Heptares Initiates Phase 1 Trial with Novel Small- Molecule CGRP Antagonist under Collaboration with Biohaven
First clinical trial with lead candidate HTL0022562 (BHV3100) to be conducted by Sosei Heptares
Candidate disc... |
| 04.06.2021 | SOSEI GROUP CORPORATION
Sosei : Notice Regarding Determination of Payment Amount and Other Matters of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan | PRESS RELEASE
Notice Regarding Determination of Payment Amount and Other Matters of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan
Tokyo, Japan and Cambridge, UK, 4 June 2021 - Sosei Group Corporation ("the Company"... |
| 19.05.2021 | SOSEI GROUP CORPORATION
Sosei Heptares : announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials | TOKYO and CAMBRIDGE, England, May 19, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new drug candidate nominat... |
| 19.05.2021 | SOSEI GROUP CORPORATION
Sosei : Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trial | PRESS RELEASE
Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
Dosing of first subject in clinical trial by Pfizer triggers US$5 million ... |
| 12.05.2021 | SOSEI GROUP CORPORATION
Sosei : Heptares Operational Highlights and Consolidated Results for the First Quarter 2021 | PRESS RELEASE
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2021
Tokyo, Japan and Cambridge, UK, 12 May 2021 - Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operati... |
| 12.05.2021 | Sosei : Consolidated Financial Results for the Three Months Ended March 31, 2021 (IFRS) | Consolidated Financial Results for the Three Months Ended March 31, 2021 (IFRS)
May 12, 2021
Company name: Sosei Group Corporation Listing: Tokyo Stock Exchange
Security code: 4565 URL: https://www.soseiheptares.com/ Representative: Shinich... |
| 12.05.2021 | Sosei : Heptares Operational Highlights and Consolidated Results for the First Quarter 2021 | PRESS RELEASE
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2021
Tokyo, Japan and Cambridge, UK, 12 May 2021 - Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operati... |
| 12.05.2021 | SOSEI GROUP CORPORATION
Sosei : Consolidated Financial Results for the Three Months Ended March 31, 2021 (IFRS) | Consolidated Financial Results for the Three Months Ended March 31, 2021 (IFRS)
May 12, 2021
Company name: Sosei Group Corporation Listing: Tokyo Stock Exchange
Security code: 4565 URL: https://www.soseiheptares.com/ Representative: Shinich... |
| 21.04.2021 | SOSEI GROUP CORPORATION
Sosei : Notice of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan | PRESS RELEASE
Notice of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan
Tokyo, Japan and Cambridge, UK, 21 April 2021 - Sosei Group Corporation ("the Company"; TSE: 4565) announces that a resolution to issue new shar... |
| 01.04.2021 | SOSEI GROUP CORPORATION
Sosei : Notice of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan | PRESS RELEASE
Notice of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan
Tokyo, Japan and London, UK, 1 April 2021 - Sosei Group Corporation ("the Company"; TSE: 4565) announces that the Company has determined the det... |
| 16.02.2021 | Sosei Heptares spin-off company Orexia Therapeutics merged into newly created Centessa Pharmaceuticals | TOKYO and CAMBRIDGE, England, Feb. 16, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) notes the announcement today from Centessa Pharmaceuticals ("Centessa") about its launch as a novel asset-ce... |
| 16.02.2021 | Sosei Heptares : spin-off company Orexia Therapeutics merged into newly created Centessa Pharmaceuticals | TOKYO and CAMBRIDGE, England, Feb. 16, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) notes the announcement today from Centessa Pharmaceuticals ("Centessa") about its launch as a novel asset-ce... |
| 12.01.2021 | Sosei Heptares and PharmEnable collaborate for AI-driven drug discovery against challenging GPCR target | Sosei Heptares and PharmEnable collaborate for AI-driven drug discovery against challenging GPCR target
12-01-2021
Sosei Group Corporation and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply the... |
| 05.01.2021 | AbbVie bails on Sosei Heptares pact for novel neurology candidates in blow to discovery outfit's A-list Rolodex | Japan’s Sosei Heptares has built a who’s who list of big-name partners looking to license the companies’ discovery-stage G protein-coupled receptors for novel neurology pathways and beyond. But with Sosei’s goal of sign... |
| 22.12.2020 | Sosei Heptares : and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design | TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA ("Captor&... |
| 22.12.2020 | SOSEI GROUP CORPORATION
Sosei Heptares : and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design | TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA ("Captor&... |
| 13.08.2020 | SOSEI GROUP CORPORATION
Sosei : Consolidated Financial Results for the Six Months Ended June 30, 2020 (IFRS) | Consolidated Financial Results for the Six Months Ended June 30, 2020 (IFRS)
August 13, 2020
Company name: Sosei Group Corporation Listing: Tokyo Stock Exchange
Security code: 4565 URL: https://www.soseiheptares.com/ Representative: Shinich... |
| 13.08.2020 | SOSEI GROUP CORPORATION
Sosei : Heptares Operational Highlights and Consolidated Results for the First Half 2020 | PRESS RELEASE
Sosei Heptares Operational Highlights and Consolidated Results for the First Half 2020
Tokyo, Japan and London, UK, 13 August 2020 - Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operationa... |
| 16.07.2020 | SOSEI GROUP CORPORATION
Sosei Heptares : Successfully Raises US$200 million in International Offering of New Shares and Convertible Bonds | TOKYO and LONDON, July 16, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) today announces the successful completion of an International Offering of new shares and euro-yen denominated convertible bonds du... |
| 25.06.2020 | AbbVie, Sosei Heptares enter $409M deal to discover, develop immunology drugs | “Collaborating with leading pharmaceutical companies is a core element of our successful value-generating strategy,” Sosei Heptares Executive Vice Chairman Malcolm Weir said in a statement. “The ability to combine our unique technology and ... |
| 25.06.2020 | Back to the immunology drawing board, AbbVie inks discovery deal with old Allergan partner | Allergan’s neurology-focused R&D pact with Sosei Heptares hasn’t been all roses, but the BD team at AbbVie found enough to like about the G protein-coupled receptor specialist’s discovery engine to kick off a new col... |
| - | ‘Truly Transformational:’ Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China) | Sosei Heptares has announced its acquisition for U.S.$466 million (JPY 65 billion) of Idorsia’s pharmaceuticals business in Japan and APAC (ex-China).
Orrick advised Sosei Heptares.
“This fully funded transaction is truly transformational a... |
| - | AbbVie, Sosei Heptares enter $409M deal to discover, develop immunology drugs | A Japanese firm that had previously partnered with a company acquired last year by AbbVie is now partnering with AbbVie itself, with a focus on drugs for autoimmune disorders.
Tokyo-based Sosei Heptares said Thursday that it had formed a dr... |
